%0 Journal Article
%T 安罗替尼治疗妇科肿瘤的有效性和安全性:一项荟萃分析
The Efficacy and Safety of Anlotinib in the Treatment of Gynecological Tumors: A Meta-Analysis
%A 陈奋
%A 王春光
%J Advances in Clinical Medicine
%P 2453-2467
%@ 2161-8720
%D 2025
%I Hans Publishing
%R 10.12677/acm.2025.153882
%X 目的:妇科肿瘤是严重危害女性健康的疾病。最常见的三种妇科肿瘤包括卵巢癌、宫颈癌和子宫内膜癌。本研究旨在评价安罗替尼治疗妇科肿瘤的疗效和安全性。方法:通过计算机检索PubMed、Cochrane library、Embase、中国知网、万方、维普、Web of Science及中国生物医学文献服务系统数据库检索相关文献。研究终点包括客观缓解率、疾病控制率、中位无进展生存期和不良事件。结果:最终共纳入16项队列研究和20项单臂研究。在疗效方面,在16项队列研究中,安罗替尼可以提高妇科肿瘤的客观缓解率和疾病控制率,结果均有统计学意义(P < 0.05)。在亚组分析中发现卵巢癌和宫颈癌的客观缓解率和疾病控制率相比化疗有所提高。在20项单臂研究中,总客观缓解率为0.353 (95% CI: 0.288~0.417),总疾病控制率为0.817 (95% CI: 0.790~0.843),总中位无进展生存期为6.095 (95% CI: 5.131~7.059)。关于安全性,最常见的不良事件包括恶心、疲劳、高血压、手足综合征和白细胞减少症。安罗替尼联合化疗组高血压和手足综合征的发生率高于单独化疗组。结论:本研究表明,安罗替尼在治疗卵巢癌、宫颈癌和子宫内膜癌方面具有显著的疗效和良好的安全性。
Objective: Gynecological tumors, including ovarian, cervical, and endometrial cancers, are serious threats to women’s health. This study aims to evaluate the efficacy and safety of anlotinib in treating these tumors. Methods: We conducted a comprehensive search of PubMed, the Cochrane Library, Embase, CNKI, WANFANG, VIP, Web of Science, and the Chinese BioMedical Literature Database for relevant studies. The primary outcomes included overall response rate (ORR), disease control rate (DCR), median progression-free survival (mPFS), and adverse events (AEs). Results: A total of 16 cohort studies and 20 single-arm studies were included. In terms of efficacy, anlotinib significantly improved ORR and DCR in gynecological cancer treatment (P < 0.05) across the 16 cohort studies. Subgroup analyses revealed similar improvements in ovarian and cervical cancers. Among the 20 single-arm studies, the pooled ORR was 0.353 (95% CI: 0.288~0.417), the pooled DCR was 0.817 (95% CI: 0.790~0.843), and the pooled mPFS was 6.095 months (95% CI: 5.131~7.059). Regarding safety, common AEs included nausea, fatigue, hypertension, hand-foot syndrome, and leukopenia. The incidence of hypertension and hand-foot syndrome was higher in patients receiving anlotinib plus chemotherapy compared to those receiving chemotherapy alone. Conclusion: This Meta-analysis indicates that anlotinib demonstrates significant efficacy and acceptable safety in treating ovarian, cervical, and endometrial cancers.
%K 安罗替尼,
%K 卵巢癌,
%K 宫颈癌,
%K 子宫内膜癌,
%K 荟萃分析
Anlotinib
%K Ovarian Cancer
%K Cervical Cancer
%K Endometrial Cancer
%K Meta-Analysis
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=110225